source
- Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressureLilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted…
- Oura and UC San Diego Health launch trial linking smart ring data to obesity treatment outcomesOura and UC San Diego Health have partnered on a multi-year clinical trial called SMART-BMI to explore how continuous data from the Oura Ring may reflect patient response to obesity therapies. The…